Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its target price cut by stock analysts at HC Wainwright from $36.00 to $34.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 179.84% from the stock’s previous close.
Other equities research analysts have also issued reports about the company. Leerink Partners started coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a “market perform” rating and a $16.00 target price for the company. Wells Fargo & Company decreased their target price on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Oppenheimer set a $30.00 price target on Nurix Therapeutics and gave the stock an “outperform” rating in a research report on Thursday, July 10th. Stephens reissued an “overweight” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Finally, UBS Group dropped their target price on Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, July 10th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.31.
View Our Latest Research Report on NRIX
Nurix Therapeutics Stock Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last issued its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.27. The business had revenue of $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. Equities research analysts forecast that Nurix Therapeutics will post -2.99 EPS for the current fiscal year.
Insider Buying and Selling at Nurix Therapeutics
In related news, insider Gwenn Hansen sold 3,377 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider owned 61,516 shares of the company’s stock, valued at approximately $707,434. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer owned 33,724 shares of the company’s stock, valued at approximately $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,013 shares of company stock worth $137,096. 7.40% of the stock is owned by insiders.
Institutional Trading of Nurix Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its holdings in Nurix Therapeutics by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 190,905 shares of the company’s stock worth $3,597,000 after acquiring an additional 15,639 shares in the last quarter. US Bancorp DE raised its holdings in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Nurix Therapeutics by 11.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 572,834 shares of the company’s stock worth $10,792,000 after acquiring an additional 61,114 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Nurix Therapeutics by 179.5% in the fourth quarter. Victory Capital Management Inc. now owns 60,212 shares of the company’s stock valued at $1,134,000 after acquiring an additional 38,672 shares during the period. Finally, Proficio Capital Partners LLC acquired a new position in Nurix Therapeutics in the 4th quarter valued at $376,000.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Recommended Stories
- Five stocks we like better than Nurix Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth
- What is the MACD Indicator and How to Use it in Your Trading
- Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Fastenal Surges After Earnings Beat, Tariff Risks Loom
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.